Intravesical Interleukin-2 in T1 Papillary Bladder Carcinoma: Regression of Marker Lesion in 8 of 10 Patients

Otter, W. Den; Dobrowolski, Zbysław; Bugajski, Andrzej; Papla, B; Meijden, A.P.M. van der; Koten, Jan-Willem; Boon, Tom A.; Siedlar, Maciej; Zembala, Marek

doi:10.1016/s0022-5347(01)63548-1

Cited by 56 publications

(31 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results do not concur with those from a previous pilot study in which the marker-lesion disappeared in 8 out of 10 (80%) patients after 2 months follow-up [17]. A possible explanation for this discrepancy could be found in the definition of a marker-lesion.…”

Section: Discussioncontrasting

confidence: 99%

“…In contrast to the literature on intravesical instillations with IL-2 [13,14,17,25,26], the number of AE in this study was high (17/26, 65%). However, most AE are known complications after TURBT and most likely not caused by the IL-2 instillations.…”

Section: Discussioncontrasting

confidence: 99%

“…Previously, our group compared 2 studies in which the effect of intravesical IL-2 instillations on the risk of recurrence in NMIBC patients was assessed [16]. In one study, 0.5-1.0 cm of tumour was left intact at TURBT as a "marker-lesion" [17], whereas in the other study, all patients were treated with complete resection [18]. Comparison of these 2 studies suggested that IL-2 is more effective in case a marker-lesion is left behind [16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial

Bosschieter¹,

Nieuwenhuijzen²,

Hentschel³

et al. 2018

Urol Int

View full text Add to dashboard Cite

Purpose: To compare the effect of intravesical interleukin-2 (IL-2) instillations with and without a marker lesion on time to recurrence (TTR) in non-muscle-invasive bladder cancer (NMIBC) patients. Methods: A prospective randomized, controlled trial was conducted. Patients with multiple non-muscle-invasive tumours were randomized for a complete or incomplete transurethral resection (TURBT), followed by 3 IL-2 instillations. The primary end point was TTR. Results: These are the results of an interim analysis, which was performed due to slow accrual after which the study was closed prematurely. Twenty-eight patients were randomized of which 17 were eligible on an intention-to-treat basis. Median TTR or last follow-up was 3 months (interquartile range [IQR] 3–10 months) for the complete and 4 months (IQR 3–8 months) for the incomplete TURBT group. The TTR between the 2 groups did not differ significantly (log-rank, p = 0.54). Conclusions: These data do not support the hypothesis that a marker lesion enhances the therapeutic effect of IL-2 instillations in patients with NMIBC.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial

Bosschieter¹,

Nieuwenhuijzen²,

Hentschel³

et al. 2018

Urol Int

View full text Add to dashboard Cite

show abstract

“…Zprávy o intravezikálním použití IL-2 odhalují významně příznivější bezpečnostní profil a prokazují i jistou míru účinnosti buď v monoterapii, či v kombinaci s BCG [40][41][42][43]. Den Otter et al podávali samotný IL-2 intravezikálně po nekompletní transuretrální resekci T1 papilárního uroteliálního karcinomu, grade I-II a prokázali regresi lézí u 8 z 10 pa cientů [44]. Další výzkumy se zaměřily na vývoj rekombinantního kmene BCG, který by produkoval IL-2 [45,46].…”

Section: S97unclassified

Immunotherapy of Urothelial Carcinoma of the Bladder – from BCG Vaccines to Targeted Therapy

Matoušková¹

2015

Klin Onkol

View full text Add to dashboard Cite

SouhrnZhoubné nádory močového měchýře postihují muže i ženy s vysokou prevalencí. Obvykle vycházejí z urotelu a více než 3/ 4 z nich bývají neinvazivní nádory močového měchýře. Základní léčebnou modalitu představuje transuretrální resekce tumoru. Její role je nezastupitelná při léčbě, ale i při stagingu nádorů močového měchýře. I u neinvazivních nádorů je standardem pokračovat lokální profylaxí s cílem snížení pravděpodobnosti rizika recidivy. Zatímco u nemocných s nízkým či středním rizikem bývá dostatečná lokální chemoprofylaxe, u vysoce rizikových neinvazivních nádorů preferujeme podání lokální imunoterapie pomocí Mycobacterium bovis bacillus Calmette-Guerin (BCG) vakcíny. U pokročilých nádorů spočívá farmakologické ovlivnění v chemoterapii samostatně nebo v kombinaci s lokoregionální léčbou. Výsledky klinických studií dokládají účinnost nových přípravků z oblasti imunoterapie i pro pokročilé ná-dory močového měchýře. Klíčová slova nádory močového měchýře -imunoterapie -BCG vakcína -kontrolní body imunitní reakce SummaryBladder cancer has high prevalence in men and women. Bladder cancer usually originates from urothelium. More than 75% of cases are classifi ed as non-muscle-invasive bladder cancer. Urothelial bladder carcinoma is usually managed by transurethral resection of the bladder tumor. Role of transurethral resection of the bladder tumor is also essential in bladder cancer staging. Local prophylaxis is used in non-muscle-invasive bladder cancer to reduce risk of recurrence. While local chemoprophylaxis is suffi cient in low and middle risk patients, intravesical instillation of Mycobacterium bovis bacillus Calmette-Guerin (BCG) is preferred in high risk bladder cancer. Chemotherapy alone or in combination with locoregional treatment is used in advanced bladder cancer. New immunotherapy modalities have proven their effi cacy in several clinical studies in advanced bladder cancer.

show abstract

“…Other cytokines that have been used intravesically include rIL-2, rIL-12, rIFN-γ and rGM-CSF. A study demonstrated that intravesical rIL-2 was beneficial for patients with T1 papillary bladder carcinoma after TURBT showing regression of marker lesions and lack of major toxic effects (Den Otter et al, 1998). Other studies also demonstrated intravesical rIL-2 to be feasible, safe and effective in patients with NMIBC who were untreated or had failed prior intravesical therapy with other agents (Tubaro et al, 1995;Ferlazzo et al, 1996).…”

Section: Combination Of Bcg With Th1 Cytokines For Bladder Cancer Trementioning

confidence: 99%

Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin: Prospective Use in Immunotherapy of Bladder Cancer

Luo¹,

Henning²,

O’Donnell³

2011

Current Cancer Treatment - Novel Beyond Conventional Approaches

View full text Add to dashboard Cite

Intravesical Interleukin-2 in T1 Papillary Bladder Carcinoma: Regression of Marker Lesion in 8 of 10 Patients

Cited by 56 publications

References 13 publications

Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial

Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial

Immunotherapy of Urothelial Carcinoma of the Bladder – from BCG Vaccines to Targeted Therapy

Th1 Cytokine-Secreting Recombinant Bacillus Calmette-Guérin: Prospective Use in Immunotherapy of Bladder Cancer

Contact Info

Product

Resources

About